# Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma

> **NCT05233293** · NA · UNKNOWN · sponsor: **First People's Hospital of Hangzhou** · enrollment: 200 (estimated)

## Conditions studied

- Extrahepatic Cholangiocarcinoma
- Malignant Biliary Obstruction

## Interventions

- **PROCEDURE:** Spyglass + RFA
- **PROCEDURE:** Cytobrush + RFA

## Key facts

- **NCT ID:** NCT05233293
- **Lead sponsor:** First People's Hospital of Hangzhou
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2023-10-01
- **Final completion:** 2023-10-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05233293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05233293, "Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05233293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*